source
- Simlukafusp Alfa Regimens Show Manageable Safety and Activity But Do Not Outperform SOC in Metastatic RCCSimlukafusp alfa plus atezolizumab with/without bevacizumab was safe and active but did not improve upon responses with SOC treatments in metastatic RCC.onclive · 3mo ago↗ source
- Dr Cohen on Frontline Chemotherapy Selection in Metastatic Pancreatic CancerDeirdre J. Cohen, MD, MS, discusses clinical decision-making and the comparative efficacy of FOLFIRINOX and NALIRIFOX in metastatic pancreatic cancer.onclive · 3mo ago↗ source
- Dr Pant on Managing Toxicities With Daraxonrasib in PDACShubham Pant, MD, MBBS, discusses the management of dermatologic and GI toxicities associated with the RAS(ON) inhibitor daraxonrasib.